Anti-pre-fusion viral F protein [MPE8]

Absolute Antibody

Anti-pre-fusion viral F protein [MPE8]

7

The antibody neutralized HRSV and HMPV, as well as PVM and BRSV, with IC50 (half-maximum inhibitory concentration) values ranging from 2 to 110 ng/ml. The antibody was also tested for its capacity to prevent cell-to-cell viral spread, showing a 50% spreading inhibiting capacity (IS50). The antibody selectively bound to the pre-fusion F protein, as shown by SPR. The antibody detected HRSV and HMPV F proteins under non-reducing conditions in western blot analysis. Further, the antibody showed prophylactic and therapeutic efficacy in vivo. In the HRSV mouse model, the antibody could reduce HRSV lung titres and was effective at concentrations as low as 0.12 mg per kg of body weight. Similar results were obtained in the HMPV mouse mode. The antibody fully protected mice from PVM lethality at 0.12 mg per kg and from body weight loss at 0.6 mg per kg. Moreover, in a therapeutic setting the antibody completely protected from lethality when administered up to 3 days after infection both at 30 and 5 mg per kg and conferred significant protection when given on day 4 or 5 at 30 mg per kg (Corti et al., 2013; PMID: 23955151). The structure of the scFv fragment in complex with the F protein of RSV was solved (Wen et al., 2017; PMID: 28134915). In ELISA analysis, the antibody bound to pre-fusion and uncleaved postfusion F, albeit with lower affinity (Gilman et al., 2015; PMID: 26161532).

Western Blot, ELISA, Neutralisation/Blocking, Other Application

Inhibition; Neutralization; WB; SPR; in vivo; crystallization; ELISA

Research Use Only

Fusion glycoprotein F0

-20°C,2°C to 8°C

12352203